| Budget Amount *help |
¥27,950,000 (Direct Cost: ¥21,500,000、Indirect Cost: ¥6,450,000)
Fiscal Year 2014: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2011: ¥14,950,000 (Direct Cost: ¥11,500,000、Indirect Cost: ¥3,450,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we investigated the safety and efficacy of intra-bone marrow administration of pure MSCs for the treatment of ovariectomy (OVX)-induced osteoporosis compared with intravenous administration. Relatively pure MSCs possessing greater potential for cell proliferation, osteogenic differentiation, and inhibition of osteoclastogenesis were obtained by magnetic activated cell sorting with the anti-Sca-1 antibody. Sca-1-sorted MSCs were administered to ovariectomized mice. As for the efficacy, intravenous administration improved bone mineral density (BMD) by increasing bone mineral content without affecting bone thickness, whereas intra-bone marrow administration improved BMD by increasing both bone mineral content and bone thickness. These results indicate that intra-bone marrow administration of MSCs is more effective approach for treating osteoporosis.
|
